In a Clinical Trial for Alzheimer’s Disease (CTAD) conference which produced no major advances against the disease, Eisai ( ESALF ) grabbed some of the headlines by suggesting that Leqembi could slow down the progression fromRetired history instructor. Alzheimer's disease researcher for the past two decades.My goal is to give investors solid advice based on the mechanisms of action of Alzheimer's drugs. This advice is informed by a background in biology (conservation, ecology, evolution, environmental scien ...